VRHI (Veri Medtech Holdings) ROCE %: -42.31% (As of Dec. 2021)


VRHI Veri Medtech Holdings Inc VRHI
35 GF Score
Price $1.95
View Full Analysis

What is Veri Medtech Holdings ROCE %?

Veri Medtech Holdings VRHI 35 ROCE % is -42.31% as of Dec. 2021. GuruFocus rates VRHI with a GF Score™ of 35/100.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Veri Medtech Holdings's annualized ROCE % for the quarter that ended in Dec. 2021 was -42.31%.

Veri Medtech Holdings  (OTCPK:VRHI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Veri Medtech Holdings ROCE % Related Terms

Veri Medtech Holdings ROCE % Historical Data

* Premium members only.

The historical data trend for Veri Medtech Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veri Medtech Holdings ROCE % Chart

Veri Medtech Holdings Annual Data
Trend Dec21
ROCE %
-42.31

Veri Medtech Holdings Semi-Annual Data
Dec21
ROCE % -42.31
VRHI
35GF Score
Veri Medtech Holdings Inc VRHI
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veri Medtech Holdings ROCE % Calculation

Veri Medtech Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2021 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2021 )  (A: . 20 )(A: Dec. 2021 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2021 )  (A: . 20 )(A: Dec. 2021 )
=/( ( ( - ) + ( - ) )/ )
=/( (+)/ )
=/
= %

Veri Medtech Holdings's ROCE % of for the quarter that ended in Dec. 2021 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2021 )  (Q: . 20 )(Q: Dec. 2021 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2021 )  (Q: . 20 )(Q: Dec. 2021 )
=/( ( ( - ) + ( - ) )/ )
=/( ( + )/ )
=/
= %

(1) Note: The EBIT data used here is one times the annual (Dec. 2021) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -42.31% mean?
Veri Medtech Holdings (VRHI) has a ROCE % of -42.31% as of Dec. 2021.
Is Veri Medtech Holdings' ROCE % too high?
Veri Medtech Holdings' current ROCE % is -42.31%. Overall, Veri Medtech Holdings has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Veri Medtech Holdings' ROCE % compare to MMVVF and BLMZ?
Veri Medtech Holdings' ROCE % of -42.31% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.41, based on 648 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veri Medtech Holdings's current ROCE % is -42.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veri Medtech Holdings stock overvalued right now?
Veri Medtech Holdings (VRHI) has a current ROCE % of -42.31%. The current ROCE % is -42.31%. Veri Medtech Holdings' overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Veri Medtech Holdings (VRHI), the current ROCE % is -42.31% as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veri Medtech Holdings Business Description

Address 1660 International Drive, Suite 600, McClean, VA, USA, 22101
Veri Medtech Holdings Inc is a healthcare technology company that offers alternative medicine, personalized diagnostics, and wellness medication on demand. The company leverages telehealth infrastructure, diagnostic intelligence, and scalable digital systems to meet the growing demand for accessible, stigma-free healthcare. Strategically positioned for growth, Veri MedTech actively explores acquisitions that complement its core capabilities and enhance patient engagement across emerging sectors of alternative medicine, longevity, and wellness science. With an integration and operational efficiency track record, the company drives accelerated revenue through the continuous generation of high-value patient databases and recurring service models.
35GF Score

Get the complete analysis for VRHI

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.95
Price